Four of the six inductees are from Houston. Photos courtesy

The Texas Business Hall of Fame Foundation has inducted six new Texans to its prestigious ranks — and four run their businesses from the Bayou City.

John Arnold, Ric Campo, Jeffery D. Hildebrand, and Paul W. Hobby — along with Austin-based Whitney Wolfe Herd and Dallas-based Thomas O. Hicks — will be honored at Texas Business Hall of Fame Foundation's 40th Anniversary and Induction Dinner on on November 3.

“The Texas Business Hall of Fame is pleased to announce its six inductees for 2022," says TBHF Chair Amanda Brock in a news release. "Inductees are recognized as trailblazers in business and exemplary leaders who have made significant contributions in their local communities and beyond, through both philanthropic and civic engagement. Although inductees can be nominated by anyone from the general public, they are selected by their peers and determined by a majority vote by Hall of Fame members."

The TBHF honors business leaders across the state by celebrating and telling their stories. The organization also runs the Future Legends Scholar & Veteran Award Program that grants forty $15,000 awards to scholars and veterans who demonstrate entrepreneurship and innovation at 24 universities throughout the Lone Star State. Both the scholars and the six honorees will celebrated this fall.

“The selection process, combined with the organization’s emphasis on both economic and social impact makes this one of the most prestigious business honors in the state,” says TBHF Legend and the 2022 Master of Ceremonies, Richard Fisher.

Here's more information on this year's honorees:

  • Houstonian John Arnold is the founder of Centaurus Capital LP, an energy-focused, family office investment fund. He also created Arnold Ventures, a philanthropic investment firm focused on health care, education, criminal justice, and public finance.
  • Houston-based Camden Property Trust CEO Ric Campo has also sat on the board of directors of several Houston organizations, including Central Houston, Inc., Greater Houston Partnership, Baker Ripley, and The Coalition for the Homeless, and more.
  • Former Dallas Stars and Dallas Rangers, owner Thomas O. Hicks, is the chairman, founder and partner of Hicks Holdings LLC, a family office that owns and manages real estate, corporate assets and investments, including a private equity firm.
  • Jeffery D. Hildebrand, is the executive chairman and founder of Houston-based Hilcorp Energy Company, Harvest Midstream Company, and JDH Capital. He serves on the boards of Central Houston, Inc., the Houston Livestock Show and Rodeo, Houston Police Foundation, Rice University’s Baker Institute for Public Policy, Chairman of The University of Texas Investment Management Company, and the Texas Parks and Wildlife Commission.
  • Houstonian Paul W. Hobby is a founding partner of Genesis Park and GP Capital. He's served as the chairman of the Texas Ethics Commission, the Greater Houston Partnership, the Houston Branch of the Federal Reserve Bank of Dallas ,and the Texas General Services Commission.
  • Austin-based Whitney Wolfe Herd is the founder and CEO of Bumble Inc., the parent company that operates Badoo, Fruitz, and Bumble, three of the world’s fastest growing data apps worldwide. She led Bumble’s IPO in 2021 as the youngest women CEO to ever take a company public.

The awards dinner, presented by Texas Capital Bank, will be hosted in Houston at Hilton Americas on November 3. The dinner is preceded by a private awards luncheon, sponsored by Deloitte, for the Hall of Fame's 40 2022 Scholar & Veteran Award recipients.

Last year's dinner honored six Texans in November 2021, including Houston investment manager Gerald Smith, chairman and CEO of Smith Graham & Co.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.


Houston researchers make headway on affordable, sustainable sodium-ion battery

Energy Solutions

A new study by researchers from Rice University’s Department of Materials Science and NanoEngineering, Baylor University and the Indian Institute of Science Education and Research Thiruvananthapuram has introduced a solution that could help develop more affordable and sustainable sodium-ion batteries.

The findings were recently published in the journal Advanced Functional Materials.

The team worked with tiny cone- and disc-shaped carbon materials from oil and gas industry byproducts with a pure graphitic structure. The forms allow for more efficient energy storage with larger sodium and potassium ions, which is a challenge for anodes in battery research. Sodium and potassium are more widely available and cheaper than lithium.

“For years, we’ve known that sodium and potassium are attractive alternatives to lithium,” Pulickel Ajayan, the Benjamin M. and Mary Greenwood Anderson Professor of Engineering at Rice, said in a news release. “But the challenge has always been finding carbon-based anode materials that can store these larger ions efficiently.”

Lithium-ion batteries traditionally rely on graphite as an anode material. However, traditional graphite structures cannot efficiently store sodium or potassium energy, since the atoms are too big and interactions become too complex to slide in and out of graphite’s layers. The cone and disc structures “offer curvature and spacing that welcome sodium and potassium ions without the need for chemical doping (the process of intentionally adding small amounts of specific atoms or molecules to change its properties) or other artificial modifications,” according to the study.

“This is one of the first clear demonstrations of sodium-ion intercalation in pure graphitic materials with such stability,” Atin Pramanik, first author of the study and a postdoctoral associate in Ajayan’s lab, said in the release. “It challenges the belief that pure graphite can’t work with sodium.”

In lab tests, the carbon cones and discs stored about 230 milliamp-hours of charge per gram (mAh/g) by using sodium ions. They still held 151 mAh/g even after 2,000 fast charging cycles. They also worked with potassium-ion batteries.

“We believe this discovery opens up a new design space for battery anodes,” Ajayan added in the release. “Instead of changing the chemistry, we’re changing the shape, and that’s proving to be just as interesting.”

---

This story originally appeared on EnergyCapitalHTX.com.